Sarep­ta shakes up C-suite as they pre­pare to test FDA on Duchenne again

Af­ter slow­ly los­ing ex­ec­u­tives over the last two years, Sarep­ta has an­nounced a host of changes at its high­est lev­el.

Sarep­ta on Mon­day an­nounced a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.